Further expansion at Randox labs with immediate start vacancies available
Further expansion at Randox labs with immediate start vacancies available
Further expansion at Randox COVID labs with recruitment drive for new staff
Randox Laboratories is hiring more new staff in support of its COVID-19 testing operations at the Randox Science Park in Antrim.
The healthcare diagnostics company has significantly increased its workforce since the beginning of the pandemic and continues to recruit to enhance its laboratory capacity within the UK’s National COVID-19 Testing Programme, and for those requiring PCR testing before travel.
Vacancies are available across science, accessioning, manufacturing and customer support.
Dr Peter FitzGerald, Managing Director of Randox Laboratories, commented;
“With our headquarters in the Randox Science Park in County Antrim, we are fortunate to benefit from Northern Ireland’s incredible talent pool across a variety of disciplines, and so many have already responded to our call for support in fighting the coronavirus.
“Our staff have risen to the challenge this pandemic has created, been incredibly resourceful and flexible, and pulled together as a team to make an impact in the fight against COVID-19. They are our best asset and we are very proud of their efforts.”
Last month Randox reached a significant testing milestone, with 21 million tests completed since its testing began.
Thanks to significant private investment, Randox’s testing capacity, which in March 2020 was just 150 tests per day, has now increased to 180,000 daily PCR tests, the same number as at the height of the pandemic.
Dr FitzGerald continued;
“The completion of over 21 million gold-standard PCR tests is testament to the hard work and dedication of all our staff.
“We continue to play a vital role in the national network of testing, which is of critical importance and remains a key part of the response to COVID-19 – not only to identify outbreaks, isolate cases and prevent further spread, but also to assist with a return to social and economic normality.”
Anyone interested in joining Randox’s COVID-19 Testing Programme should apply at https://randox.getgotjobs.co.uk/
Job roles available include:
- Laboratory Analysts
- Sample Processing Operatives
- Laboratory Support
- Customer Support Advisors
- Manufacturing Technicians
Want to know more?
Contact us or visit Randox Careers
Related Pages
CAREERS NEWS
VACANCIES
OUR PEOPLE
STAFF PROFILES
Evaluation of Omicron Variant to Ensure Test Effectiveness
7th December 2021
Evaluating Omicron and Other SARS-CoV-2 Variants to Ensure Test Effectiveness
SARS-CoV-2, like all viruses, evolves over time through mutations, as it spreads and replicates. Since the beginning of the COVID-19 pandemic, many variants of the SARS-CoV-2 virus, with different sets of mutations, have been observed worldwide. Most changes have little impact on the virus’ properties. However, some may cause increased transmissibility, severity of disease or the ability to evade the host immune response. Surveillance of genetic variations is therefore crucial to identify those variants which pose a higher risk to human health.
Variants may impact the performance of current diagnostic approaches. This is why Randox continuously review public genomic databases to assess whether any emerging mutations overlap with the assay design and monitor assay performance as part of post-market surveillance efforts to ensure the coronavirus assays continue to meet the highest quality standards.
In light of the emergence of the new variant of concern detected in South Africa, Omicron (B.1.1.529), Randox have analysed all publicly available sequences of the variant to predict any impact of defining mutations on assay designs.
As the COVID-19 assays from Randox Laboratories Ltd. are designed using a dual-target approach (ORf1ab, E gene) to reduce the impact of genetic variation in the SARS-CoV-2 genome, detection of SARS-CoV-2 is not predicted to be affected by the currently known variants.
Detection of SARS-CoV-2 using the Vivalytic rapid RT-PCR tests, targeting the E gene sequence are not affected by the identified mutations. Assay performance is not predicted to be impaired by the current known variants.
Randox Laboratories Ltd., in collaboration with leading technology manufacturer Bosch Healthcare Solutions, have developed a range of COVID-19 testing solutions, providing clear and concise results in a timely manner, directly at the point of care. Randox is a distributor for Vivalytic platform and cartridges.
For all enquiries regarding our COVID-19 assays performance , please contact marketing@randox.com
Randox in the media
Latest News
FAQs
Randox welcomes CMA moves to safeguard consumer interests around PCR testing
3rd December 2021
Randox Statement: Randox welcomes CMA moves to safeguard consumer interests around PCR testing
Responding to today’s announcement by the Competition and Markets Authority (CMA), a spokesman for Randox said:
“We welcome the role played by the CMA, with our full co-operation, in ensuring that consumers continue to get a fair deal during the Covid emergency.
“Randox has been happy to engage fully with the CMA from the outset to ensure in the interests of its customers while the company delivers millions of Covid-19 PCR tests to facilitate vital international travel against the changing requirements of governments.
“As the industry leader, Randox has been in the ideal position to both review the services required to support the international traveller and provide a consumer-industry standard of Terms and Conditions. These have, of necessity, evolved over time.
“In working with the CMA, Randox’s aim has been to ensure absolute fairness whilst building and providing critical services in a highly volatile and demanding environment.”
Additional Information
Randox has today welcomed engagement with the CMA to optimise Covid-19 PCR testing support for international travel whilst ensuring the sustainability of critical national services.
As the industry leader Randox has been in the ideal position to both review the services required to support the international traveller, and provide a consumer-industry standard of Terms and Conditions, which have evolved over time. In working with the CMA Randox’s aim has been to ensure absolute fairness whilst building and providing critical services in a highly volatile and demanding environment.
“Both industry and the travelling public have faced significant pressures in enabling international travel,” said a spokesperson. “From an industry perspective Government required immediate and large scale investment to establish validated end-to-end testing services, supported by nationwide logistics, with fully secure reporting to both individuals and Government. Yet there were no contracts, no expected duration for services and the requirement was based on a single product – Covid-19 PCR testing. It was also evident that Government would remove the requirement for such testing as soon as practicable and would not provide any further support.”
The spokesperson went on; “At the same time as requiring significant investment and a rapid response from industry, Government retained the right to alter demand on an almost daily basis and did so frequently by moving countries between the green, amber and red lists with no notice. Government subsequently removed the country lists entirely and effectively closed the requirements for international travel PCRs by moving to lateral flow devices in October – only months after establishing services.” The decision by the Prime Minister to reintroduce PCR testing at very short notice this week, without prior notice to industry, further illustrates the challenges faced.
It had also been clear that the public were faced with highly variable pricing by a number of suppliers – some advertising low prices, but which were only available in very limited circumstances – something Grant Shapps asked the CMA to review. “From the very start Randox committed to highly competitive and transparent pricing which was available across the nation,” said the spokesperson. “Our home testing kits are available at an all inclusive price of £43 with a click and collect service at £34.99 – we know that these represent excellent value for money.”
Randox’s engagement with the CMA has provided the ability to review consumer-industry terms and conditions in the light of very hard won experience. “We do hope that other providers will consider our terms and conditions,” said the spokesperson, “and we know that the CMA will provide further guidance where required.”
The spokesperson went on; “We at Randox are very proud of what we have achieved in very demanding and volatile circumstances. We have built and sustained a reliable and cost effective service to enable international travel – meeting critical business needs and ensuring friends and families can continue to meet. We are committed to providing this service for as long as Government requires.”
For all media enquiries, please contact Ian Monk on ian@ianmonk.com or +44 7970 026072 / + 44 203 011 1933